Liquidia Technologies (LQDA) vs. Anika Therapeutics (ANIK) Financial Review

Liquidia Technologies (NASDAQ:LQDA) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Earnings and Valuation

This table compares Liquidia Technologies and Anika Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Liquidia Technologies N/A N/A N/A N/A N/A
Anika Therapeutics $113.42 million 5.41 $31.81 million $1.96 21.46

Anika Therapeutics has higher revenue and earnings than Liquidia Technologies.


This table compares Liquidia Technologies and Anika Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Liquidia Technologies N/A N/A N/A
Anika Therapeutics 16.94% 9.53% 8.85%

Institutional & Insider Ownership

94.8% of Anika Therapeutics shares are held by institutional investors. 6.6% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Liquidia Technologies and Anika Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liquidia Technologies 0 0 4 0 3.00
Anika Therapeutics 0 1 2 0 2.67

Liquidia Technologies currently has a consensus price target of $29.50, indicating a potential upside of 17.44%. Anika Therapeutics has a consensus price target of $41.00, indicating a potential downside of 2.52%. Given Liquidia Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Liquidia Technologies is more favorable than Anika Therapeutics.


Anika Therapeutics beats Liquidia Technologies on 6 of the 9 factors compared between the two stocks.

About Liquidia Technologies

There is no company description available for Liquidia Technologies Inc.

About Anika Therapeutics

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with's FREE daily email newsletter.

Leave a Reply